GleamWall
中文EN

NIKA NIKA PHARMACEUTICALS, INC

Pharmaceutical Preparations · OTC · SEC CIK 1145604 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-60.7%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-574.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets6,574.0%
Debt / equity—
Current ratio0.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-85.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
SG&A expense$8,177$14,848$2,639$33,023$3,901$14,300$1,800$6,358
Operating income-$13,023-$19,694-$13,359-$37,089-$7,982-$18,381-$12,945-$12,453
Pretax income-$13,023-$19,694-$13,359-$37,089-$7,982-$18,381-$12,945-$12,453
Net income-$13,023-$19,694-$13,359-$37,089-$7,982-$18,381-$12,945-$12,453
EPS (basic)0.000.000.00—0.000.000.00—
EPS (diluted)0.000.000.00—0.000.000.00—
Weighted avg. shares (diluted)1.05B1.05B1.05B—1.04B1.03B1.03B—
Balance sheet
Cash & equivalents$352$2,932$1,530$1,889$6,287$15,616$19,137$2,083
Current assets$5,309$9,942$20,637$20,996$23,625$31,607$34,988$17,934
Total assets$5,309$9,942$20,637$20,996$23,625$31,607$34,988$17,934
Current liabilities$349,014$340,624$331,624$318,624$284,164$284,164$269,164$239,164
Short-term debt$349,014$340,624$331,624$318,624$284,164$284,164$269,164$239,164
Total liabilities$349,014$340,624$331,624$318,624$284,164$284,164$269,164$239,164
Shareholders' equity-$343,705-$330,682-$310,988-$297,628-$260,539-$252,557-$234,176-$221,231
Shares outstanding1.05B1.05B1.05B1.05B1.04B1.03B1.03B1.05B
Cash flow statement
Operating cash flow-$10,970-$7,598-$13,359-$38,858-$9,329-$18,522-$12,945-$12,452
Financing cash flow$8,390$9,000$13,000$34,460$0$15,000$30,000$29,000

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.